- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 17, 2023
Discovery & Translation
Improved transgene insertion; plus Synlogic’s autoimmune probiotic and more
BioCentury’s roundup of translational innovations
BioCentury | May 28, 2020
Deals
In its first broad deal, Repare leads BMS deeper into synthetic lethality
BioCentury | Aug 17, 2019
Emerging Company Profile
Impact casting a wide synthetic lethality net
Impact aims to build synthetic lethality pipeline of validated DNA damage repair, novel targets
BioCentury | Jun 7, 2019
Targets & Mechanisms
Following PARP, ATR axis next in line to expand synthetic lethal drug class
As companies search for the successor to PARP, the ATR axis becomes a key contender
BioCentury | Jun 15, 2017
Clinical News
Merck reports Phase Ia data for DNA-PK inhibitor M3814 in solid tumors
BioCentury | Jun 15, 2017
Clinical News
Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors
Items per page:
1 - 10 of 17